SCHEMBL4334972

SCHEMBL4334972

COc1c(C(=O)NCc2ccc(C)o2)ccc2[nH]nc(-c3cc4ccccc4s3)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
ALDH1A1 P00352 6/20 0.38
PKM P14618 5/20 0.38
HSD17B10 Q99714 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
ALOX12 P18054 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 6/20 0.38
MAPK10 P53779 1/20 0.37
KDM4E B2RXH2 3/20 0.37
HTT P42858 1/20 0.37
PDE10A Q9Y233 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4332224 0.88 MAPT (0.46) ALDH1A1PKMHSD17B10SMN1; SMN2MEN1
SCHEMBL4334979 0.86 MAPT (0.44) ALDH1A1PKMHSD17B10SMN1; SMN2MEN1
SCHEMBL4333025 0.84 ALDH1A1 (0.41) JAK2JAK3ALDH1A1PKMHSD17B10
SCHEMBL4329228 0.84 HPGD (0.44) JAK2JAK3ALDH1A1HSD17B10SMN1; SMN2
SCHEMBL4333960 0.84 MAPK10 (0.37) JAK2JAK3ALDH1A1SMN1; SMN2HPGD
SCHEMBL4327612 0.84 JAK2 (0.40) JAK2JAK3ALDH1A1PKMHSD17B10
SCHEMBL2865451 0.83 MAPK10 (0.42) JAK2JAK3MAPK10
SCHEMBL2867630 0.83 SMN1; SMN2 (0.51) ALDH1A1SMN1; SMN2HPGDMAPTKDM4E
SCHEMBL13635937 0.83 MAPK10 (0.40) JAK2JAK3MAPK10TNIKMAPKAPK2
SCHEMBL4334929 0.82 LMNA (0.41) JAK2JAK3MAPTMAPK10TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 JAK2 145/4885JAK3 776/4885ALDH1A1 1588/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 JAK2 145/4885JAK3 776/4885ALDH1A1 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.